Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the ...
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...
Reuters16d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
ZURICH, March 12 (Reuters) - Roche (ROG.S), opens new tab has acquired rights to an obesity therapy by Denmark's Zealand Pharma (ZELA.CO), opens new tab in a collaboration deal worth up to $5.3 ...
STAT15d
Roche partners with Zealand Pharma to push forward obesity drug
Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its ...
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...
NBC New York15d
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate, as the two firms seek to ...
Wall Street Journal15d
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment as the companies double down on ...